Ergosterol-containing membrane of Leishmania species

The ergosterol-containing membrane of Leishmania species refers to the parasite's plasma membrane, which is rich in ergosterol rather than cholesterol as in mammalian cells[3][4]. This unique lipid composition is essential for membrane fluidity, integrity, and adaptation to host environments[3][4][1]. Ergosterol is synthesized via a branched biosynthetic pathway distinct from the cholesterol pathway in mammals[2][4]. This difference has been exploited therapeutically, with drugs such as amphotericin B binding directly to ergosterol to disrupt membrane function and cause parasite death[2][4]. Inhibitors of ergosterol biosynthesis (e.g., azoles targeting CYP51) also demonstrate anti-leishmanial effects[2][4]. The plasma membrane's ergosterol content is vital for the parasite’s survival, immune evasion (by modulating membrane proteins and lipid rafts), resistance to oxidative stress, and drug resistance[3][5][1]. Leishmania’s ergosterol-rich membrane is thus a well-established therapeutic target in drug development against leishmaniasis[4][2].

Other names

Leishmania plasma membraneLeishmania ergosterol-rich membraneLeishmania cell membrane

Direct binding to membrane ergosterol (e.g. amphotericin B forms pores, increasing membrane permeability) Inhibition of ergosterol biosynthesis (e.g. azoles like posaconazole and fluconazole inhibit sterol 14α-demethylase/CYP51, reducing ergosterol content)